---
title: "Bell Potter Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)"
description: "According to TipRanks, Hester is a 4-star analyst with an average return of 11.8% and a 55.56% success rate. Hester covers the Healthcare sector, focusing on stocks such as Telix Pharmaceuticals, Sigm"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/259219939.md"
published_at: "2025-09-28T14:05:06.000Z"
---

# Bell Potter Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)

> According to TipRanks, Hester is a 4-star analyst with an average return of 11.8% and a 55.56% success rate. Hester covers the Healthcare sector, focusing on stocks such as Telix Pharmaceuticals, Sigma Healthcare Ltd, and Mesoblast Limited. In addition to Bell Potter, Telix Pharmaceuticals also received a Buy from Morgan Stanley’s David Bailey in a report issued on September 23. However, on September 24, TR | OpenAI – 4o reiterated a Hold rating on Telix Pharmaceuticals (Other OTC: TLPPF).

According to TipRanks, Hester is a 4-star analyst with an average return of 11.8% and a 55.56% success rate. Hester covers the Healthcare sector, focusing on stocks such as Telix Pharmaceuticals, Sigma Healthcare Ltd, and Mesoblast Limited.

In addition to Bell Potter, Telix Pharmaceuticals also received a Buy from Morgan Stanley’s David Bailey in a report issued on September 23. However, on September 24, TR | OpenAI – 4o reiterated a Hold rating on Telix Pharmaceuticals (Other OTC: TLPPF).

### Related Stocks

- [TLX.US - Telix Pharmaceuticals](https://longbridge.com/en/quote/TLX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Telix 2025 全年業績投資者網絡直播通知 \| TLX 股票新聞 | Telix Pharmaceuticals Limited（ASX: TLX，NASDAQ: TLX）將於 2026 年 2 月 20 日發佈 2025 財年的全年業績，並於澳大利亞東部夏令時間上午 9:30 舉行投資者網絡直播。該公司專注 | [Link](https://longbridge.com/en/news/274715952.md) |
| 澳大利亞的 Telix Pharmaceuticals 跌至兩年多來的最低點，因董事長辭職 | 澳大利亞 Telix Pharmaceuticals 的股價本週迄今下跌 7.3%，如果損失持續，將創下自 12 月 19 日結束的那一週以來的最大周跌幅 ** 今日股價下跌 3.5%，為 2024 年 1 月 10 日以來的最低點 **  | [Link](https://longbridge.com/en/news/275068806.md) |
| Medexus Pharmaceuticals 公佈第三季度財報結果 | Medexus Pharmaceuticals 公佈第三季度業績 | [Link](https://longbridge.com/en/news/275670725.md) |
| Evercore ISI 維持對 CVS Health（西維斯）的買入評級 | Evercore ISI 分析師 Elizabeth Anderson 對 CVS Health (CVS) 維持了買入評級，目標價為 100.00 美元。Anderson 專注於醫療保健行業，推薦的平均回報率為 -2.1%，成功率為 48 | [Link](https://longbridge.com/en/news/275622408.md) |
| Citius Pharmaceuticals, Inc. 宣佈在成功推出 LYMPHIR™後首次實現收入 \| CTOR 股票新聞 | Citius Pharmaceuticals, Inc. 報告稱，2025 年 12 月推出的 LYMPHIR™ 實現了 390 萬美元的收入，標誌着其轉型為一家產生收入的公司。該公司旨在通過其技術驅動的平台擴大市場影響力並增強患者的可及性 | [Link](https://longbridge.com/en/news/275904512.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.